Belite Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Employees
- 20
- Market Cap
- $1.4B
- Website
- http://www.belitebio.com
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Belite Bio, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT06388083
- Locations
- 🇬🇧
Bellite Study Site, London, United Kingdom
🇯🇵Belite Study Site, Tokyo, Japan
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Belite Bio, Inc
- Target Recruit Count
- 429
- Registration Number
- NCT05949593
- Locations
- 🇬🇧
Belite Study Site, London, United Kingdom
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
Phase 3
Active, not recruiting
- Conditions
- Stargardt Disease 1
- Interventions
- Drug: PlaceboDrug: Tinlarebant
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Belite Bio, Inc
- Target Recruit Count
- 104
- Registration Number
- NCT05244304
- Locations
- 🇬🇧
Belite Study Site, Southampton, United Kingdom
Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BPN-14967Drug: Placebo
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Belite Bio, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04005807
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath